TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
Stock Information for Kintara Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.